Clinical Research Directory
Browse clinical research sites, groups, and studies.
Chinese Adults With Kidney Disease
Sponsor: ADARx Pharmaceuticals, Inc.
Summary
This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).
Official title: A Phase 2 Study to Assess ADX-038 in Chinese Adults With Complement-Mediated Kidney Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-07-23
Completion Date
2029-01-21
Last Updated
2026-05-01
Healthy Volunteers
No
Interventions
ADX-038
siRNA duplex oligonucleotide
Telitacicept
fusion protein
Locations (10)
ADARx Clinical Site
Shenzhen, Guangdong, China
ADARx Clinical Site
Guiyang, Guizhou, China
ADARx Clinical Site
Zhengzhou, Henan, China
ADARx Clinical Site
Baotou, Inner Mongolia, China
ADARx Clinical Site
Wuxi, Jiangsu, China
ADARx Clinical Site
Yantai, Shandong, China
ADARx Clinical Site
Beijing, China
ADARx Clinical Site
Shandong, China
ADARx Clinical Site
Shanghai, China
ADARx Clinical Site
Shangxi, China